Clinical Trial Update: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype [Phase 3]

View source ↗

Summary

Phase 3 study comparing depemokimab (GSK3511294) with mepolizumab or benralizumab in participants with severe eosinophilic asthma; the trial status is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Benralizumab (benralizumab)
• Depemokimab (depemokimab)
• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED